These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 30294626)

  • 1. Dataset on the response of Hut78 cells to novel rexinoids.
    Hackney Price J; Hanish BJ; Wagner CE; Kaneko I; Jurutka PW; Marshall PA
    Data Brief; 2018 Oct; 20():1797-1803. PubMed ID: 30294626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel gene expression analytics-based approach to structure aided design of rexinoids for development as next-generation cancer therapeutics.
    Hanish BJ; Hackney Price JF; Kaneko I; Ma N; van der Vaart A; Wagner CE; Jurutka PW; Marshall PA
    Steroids; 2018 Jul; 135():36-49. PubMed ID: 29704526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methods to Assess Activity and Potency of Rexinoids Using Rapid Luciferase-Based Assays: A Case Study with NEt-TMN.
    Jurutka PW; Wagner CE
    Methods Mol Biol; 2019; 2019():95-108. PubMed ID: 31359391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action.
    Zhang C; Hazarika P; Ni X; Weidner DA; Duvic M
    Clin Cancer Res; 2002 May; 8(5):1234-40. PubMed ID: 12006543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results.
    Duvic M; Hymes K; Heald P; Breneman D; Martin AG; Myskowski P; Crowley C; Yocum RC;
    J Clin Oncol; 2001 May; 19(9):2456-71. PubMed ID: 11331325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methods to Generate an Array of Novel Rexinoids by SAR on a Potent Retinoid X Receptor Agonist: A Case Study with NEt-TMN.
    Wagner CE; Jurutka PW
    Methods Mol Biol; 2019; 2019():109-121. PubMed ID: 31359392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bexarotene Reduces Production of CCL22 From Tumor-Associated Macrophages in Cutaneous T-Cell Lymphoma.
    Tanita K; Fujimura T; Sato Y; Lyu C; Kambayashi Y; Ogata D; Fukushima S; Miyashita A; Nakajima H; Nakamura M; Morita A; Aiba S
    Front Oncol; 2019; 9():907. PubMed ID: 31616630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Testing Novel Pyrimidinyl Rexinoids: A New Paradigm for Evaluating Rexinoids for Cancer Prevention.
    Zhang D; Leal AS; Carapellucci S; Shahani PH; Bhogal JS; Ibrahim S; Raban S; Jurutka PW; Marshall PA; Sporn MB; Wagner CE; Liby KT
    Cancer Prev Res (Phila); 2019 Apr; 12(4):211-224. PubMed ID: 30760500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma.
    Scarisbrick JJ; Morris S; Azurdia R; Illidge T; Parry E; Graham-Brown R; Cowan R; Gallop-Evans E; Wachsmuth R; Eagle M; Wierzbicki AS; Soran H; Whittaker S; Wain EM
    Br J Dermatol; 2013 Jan; 168(1):192-200. PubMed ID: 22963233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic advances in cutaneous T-cell lymphoma (CTCL): from retinoids to rexinoids.
    Stadler R; Kremer A
    Semin Oncol; 2006 Feb; 33(1 Suppl 3):S7-10. PubMed ID: 16516669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Absence of modulation of CD4+CD25 regulatory T cells in CTCL patients treated with bexarotene.
    Knol AC; Quéreux G; Brocard A; Ballanger F; Khammari A; Nguyen JM; Dréno B
    Exp Dermatol; 2010 Aug; 19(8):e95-102. PubMed ID: 19845755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging role of rexinoids in non-small cell lung cancer: focus on bexarotene.
    Rigas JR; Dragnev KH
    Oncologist; 2005 Jan; 10(1):22-33. PubMed ID: 15632250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mass spectrometry and DigiWest technology emphasize protein acetylation profile from Quisinostat-treated HuT78 CTCL cell line.
    Méhul B; Perrin A; Grisendi K; Galindo AN; Dayon L; Ménigot C; Rival Y; Voegel JJ
    J Proteomics; 2018 Sep; 187():126-143. PubMed ID: 30012418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural and Structure-based RXR Ligand Scaffolds and Their Functions.
    Dominguez M; Alvarez S; de Lera AR
    Curr Top Med Chem; 2017; 17(6):631-662. PubMed ID: 27320335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bexarotene: a clinical review.
    Farol LT; Hymes KB
    Expert Rev Anticancer Ther; 2004 Apr; 4(2):180-8. PubMed ID: 15056048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of biomarkers regulated by rexinoids (LGD1069, LG100268 and Ro25-7386) in human breast cells using Affymetrix microarray.
    Seo HS; Woo JK; Shin YC; Ko SG
    Mol Med Rep; 2015 Jul; 12(1):800-18. PubMed ID: 25778982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rexinoids isolated from Sophora tonkinensis with a gene expression profile distinct from the synthetic rexinoid bexarotene.
    Inoue M; Tanabe H; Nakashima K; Ishida Y; Kotani H
    J Nat Prod; 2014 Jul; 77(7):1670-7. PubMed ID: 24959987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of cutaneous T cell lymphoma: current status and future directions.
    Apisarnthanarax N; Talpur R; Duvic M
    Am J Clin Dermatol; 2002; 3(3):193-215. PubMed ID: 11978140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ECPIRM, a Potential Therapeutic Agent for Cutaneous T-Cell Lymphoma, Inhibits Cell Proliferation and Promotes Apoptosis via a JAK/STAT Pathway.
    Yang H; Ma P; Cao Y; Zhang M; Li L; Wei J; Tao L; Qian K
    Anticancer Agents Med Chem; 2018; 18(3):401-411. PubMed ID: 28356009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of refractory early-stage cutaneous T-cell lymphoma.
    Huber MA; Staib G; Pehamberger H; Scharffetter-Kochanek K
    Am J Clin Dermatol; 2006; 7(3):155-69. PubMed ID: 16734503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.